Cardiovascular

Mouse studies suggest the pan-BCR-ABL tyrosine kinase inhibitor (TKI) Iclusig ponatinib could help treat cerebral cavernous malformation (CCM). In three mouse models of CCM, Iclusig decreased hindbrain lesion volume and counts compared with no treatment. In a fourth mouse model of CCM, Iclusig decreased lesion volume. Next steps could include clinical trials of Iclusig in CCM patients...